Clinical Study of Plasmodium Immunotherapy for Advanced Non-small Cell Lung Cancer

Trial Profile

Clinical Study of Plasmodium Immunotherapy for Advanced Non-small Cell Lung Cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Plasmodium vivax immunotherapy (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Dec 2017 Planned number of patients changed from 80 to 30.
    • 17 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top